secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001213900-24-109891
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed enters $10M standby equity facility with Yorkville; shares at 97% of VWAP
-------------------------------------------------------------------------------

- Up to $10M common shares may be sold to YA II PN, Ltd (Yorkville) at 97% of lowest daily VWAP over 3-day pricing period.
- Facility runs until Jan 1, 2027 (~36 months); issuance capped at 19.99% of outstanding (unless pricing conditions met).
- Company pays $25k structuring fee plus 2.50% commitment fee ($250k) – 25% cash upfront, 75% deferred quarterly.
- Proceeds for working capital and general corporate purposes; CEO cites flexibility and extended runway.
- Sales at company's discretion; no obligation to sell any shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024109891/0001213900-24-109891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024109891/ea0225022-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-109891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer